Secukinumab is a biologic agent that is increasingly being utilized in clinical practice as an interleukin-17 inhibitor, as evidenced in numerous psoriasis treatment guidelines, which identify this agent as a primary therapeutic option for psoriasis [2]. Here, IL17A is linked to psoriasis.